Colitis persistent inflammation underlying disease known to migrate. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn’s disease and other inflammatory diseases of the the gastrointestinal system.
He hopes by mid 2008.
About Traficet-EN Traficet-EN is a small molecule, orally available drug that is administered in capsule form and is believed to the inappropriate immune system response underlying inflammatory bowel disease control by blocking the CCR9 chemokine receptor. CCR9 in adults is a highly specific receptor expressed by T cells , which migrate selectively to the digestive tract. The trading of T cells to the small and large intestine causes persistent inflammation that can Crohn’s disease or ulcerative colitis result – the two main forms of IBD. In preclinical studies, the compound was both therapeutically and prophylactically in models of colitis, Crohn’s disease and colitis. In addition to the ongoing PROTECT – 1 clinical trial in Crohn’s disease, is Traficet-EN that, for patients with celiac disease over 500,000 patients to gluten and gluten derivatives in which digestive tract thought to play thought to play an important role analyzed.Wife Cynthia Robitaille, Public Health Agency of Canada, with a co-authors, said:’If the 2007/09 remain age-and sex specific incidence and mortality rates constant, we expect that about 26.4 million) of Canadian adults lives living diagnosed with hypertension 2015 thirteenths. ‘.
The investigation was the Institute from researchers from which Public Health Agency of Canada, Public Health Ontario, University of Calgary, the Institute of Clinical Evaluative Sciences in, with the British Columbia the Ministry of Health Services, which made Manitoba Centre for Health Policy and nationalist Sant? publique you Qu?